You're viewing
Met-Plus-G2 Tablet SR
RxBi-Cure Remedies
₹115 Out of stock
View details Composition: Glimepiride 2mg + Metformin 1000mg
Met-Plus-G2 Tablet SR is out of stock right now
Good news — 79 medicines with the same composition are listed below and can be ordered instead.
Save up to ₹47 (41%) with a generic
Cheapest in-stock substitute: RAYGLIM M 2/1000
A like-for-like swap — identical active ingredients, same strength and form as Met-Plus-G2 Tablet SR.
Same active ingredient(s) but a different strength or form — check the strength matches your prescription.
Glimepiride2mg
Full details →Glimepiride is an oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels and preventing the symptoms associated with diabetes. Glimepiride is often prescribed alongside diet and exercise to enhance glycemic control and reduce the risk of diabetes-related complications, such as kidney damage and neuropathy. In summary, Glimepiride is an essential medication for controlling blood sugar levels in type 2 diabetes patients.
Metformin1000mg
Full details →Metformin is an oral antihyperglycemic agent used to manage type 2 diabetes mellitus. It works by decreasing glucose production in the liver and improving insulin sensitivity. Metformin is effective in controlling blood sugar levels and preventing diabetes-related complications. In summary, Metformin is vital for managing type 2 diabetes.
Same active ingredient
A substitute has the exact same salt(s) — so it works the same way as the brand.
Often much cheaper
Generics can cost a fraction of the branded price for the identical molecule.
Quality-regulated
All medicines we list are from licensed sellers and meet the same standards.
Substitutes share the same active ingredients, but always confirm the strength and form with your doctor or pharmacist before switching — especially for chronic, prescription or narrow-therapeutic-index medicines.
